Pharmaceutisch Weekblad

, Volume 14, Issue 3, pp 146–151 | Cite as

Δ2-Valproate biotransformation using human liver microsomal fractions

  • Gérard Fabre
  • Christophe Briot
  • Eric Marti
  • Jean -Pierre Montseny
  • Martine Bourrié
  • Danielle Massé
  • Yves Berger
  • Jean -Paul Cano
Recent Developments on Valproate and its Metabolites


The metabolism of 2-n-propyl-2-pentenoate (Δ2-VPA) was evaluated in human hepatic microsomal fractions. Two biotransformation pathways have been particularly investigated. In the presence of the cytochrome P-450 co-factor, NADPH, the main metabolites recovered were Δ3-VPA, Δ2,4-VPA and VPA. The glucuronidation of Δ2-VPA was also studied on various hepatic microsomal fractions using Brij® 35 as activator and UDP-glucuronic acid as co-factor. A large interindividual variability occurred in this metabolic pathway.K m andVmax were 0.85 mmol/l and 1.75 nmol·min−1·mg−1, respectively, for Δ2-VPA and 1.11 mmol/l and 5.71 nmol·min−1·mg−1 for VPA, respectively. The good correlationr=0.82; p<0.001) observed between the glucuronidation of VPA and Δ2-VPA as well as the mutual inhibition of each other's glucuronidation strongly suggests that (a) common single UDP-glucuronosyltransferase isoenzyme(s) was (were) involved in this glucuronidation step. The glucuronidation of specific substrates for various UDP-glucuronosyltransferase isoenzymes showed a good relationship between the glucuronidations of Δ2-VPA and morphine, a substrate for UDP-glucuronosyltransferase-2B. Moreover, morphine competitively inhibits A -VPA glucuronidation. It seems the same isoenzyme or, at least, (a) very closely related isoenzyme(s) belonging to UDP-glucuronosyltransferase-2 isoenzyme, is involved in Δ2-VPA glucuronidation.


Biotransformation Cytochrome P-450 Isoenzymes Microsomes, liver 2-n-Propyl-2-pentenoic acid UDP glucuronosyltransferase Valproic acid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bourgeouis BFD. Valproate; clinical use. In: Levy RH, Dreyfuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989:633–42.Google Scholar
  2. 2.
    Granneman GR, Wang SI, Machinist JM, Kesterson JW. Aspects of the metabolism of valproic acid. Xenobiotica 1984;14:375–87.PubMedGoogle Scholar
  3. 3.
    Nau H. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse. Teratology 1986;33:21–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Lewandowski C, Klug S, Nau H, Neubert D. Pharmacokinetic aspects of drug effectsin vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en valproic acid. Arch Toxicol 1984;58:239–42.CrossRefGoogle Scholar
  5. 5.
    Loscher W, Nau H. Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences. Arch Int Pharmacodyn Ther 1984;279:199–202.Google Scholar
  6. 6.
    Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. 1. Toxicologic, biochemical and histopathologic studies. Hepatology 1984;4:1143–52.PubMedGoogle Scholar
  7. 7.
    Nau H, Loscher W. Valproic acid and active unsaturated metabolite (2-en): transfer to mouse liver following human therapeutic doses. Biopharm Drug Dispos 1985;6:1–8.PubMedGoogle Scholar
  8. 8.
    Fabre G, Crevat-Pisano P, Dragna S, Covo J, Barra Y, Cano JP. Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochem Pharmacol 1988;47:1947–53.CrossRefGoogle Scholar
  9. 9.
    Von Bahr C, Groth CG, Jansonn H, Lundgren G, Lind K, Glaumann H. Drug metabolism in human liverin vitro: establishment of a human liver bank. Clin Pharmacol Ther 1980;27:711–25.PubMedGoogle Scholar
  10. 10.
    Pollard HB, Menard R, Brandt HA, Pazoles CJ, Creutz CE, Ramu A. Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 1978;86:761–3.CrossRefPubMedGoogle Scholar
  11. 11.
    Rettenmeier AW, Howald WN, Levy RH, Witek DJ, Gordon WP, Porubek DJ, et al. Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques. Biomed Environ Mass Spect 1989;18:192–9.CrossRefGoogle Scholar
  12. 12.
    Miners JO, Lillywhite KJ, Matthews AP, Jones ME, Birkett DJ. Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. Biochem Pharmacol 1988; 37:665–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Sanchez E, Tephly TR. Morphine metabolism. I. Evidence for separate enzymes in the glucuronidation of morphine andp-nitrophenol by rat hepatic microsomes. Drug Metab Dispos 1974;2:247–53.PubMedGoogle Scholar
  14. 14.
    Schuetz EG, Hazelton GA, Hall J, Watkins PB, Klaassen CD, Guzelian PS. Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem 1986;261:8270–5.PubMedGoogle Scholar
  15. 15.
    Van Roy FP, Heirwegh KPM. Determination of bilirubin glucuronide and assays of glucuronosyl transferase with bilirubin as acceptor. Biochem J 1968;107:507–18.PubMedGoogle Scholar
  16. 16.
    Prickett KS, Baillie TA. Metabolism of valproic acid by hepatic microsomal cytochrome P-450. Biochem Biophys Res Comm 1984;122:1166–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Dixon M, Webb EC. Enzymes. 3rd ed. New York: Academic Press, 1979:47–206.Google Scholar
  18. 18.
    Dixon M, Webb EC. Enzymes: Orlando: Academic Press, 1964:5–166.Google Scholar
  19. 19.
    Miners JO, Lillywhite KJ, Matthews AP, Birkett DJ.In vitro assessment of UDP-glucuronosyltransferase multiplicity and substrate specificity in human liver. In: Miners J, Birkett R, Drew R, McManus M, eds. Microsomes and drug oxidations. London: Taylor and Francis, 1988:279–86.Google Scholar
  20. 20.
    Tephly TR, Coffman BL, Falany CN, Green MD, Irshaid Y, Puig JF, et al. Purification and characterization of mammalian UDP-glucuronosyltransferases. In: Miners J, Birkett DJ, Drew R, McManus M, eds. Microsomes and drug oxidations. London: Taylor and Francis, 1988:263–70.Google Scholar
  21. 21.
    MacKenzie PI, Haque SJ. Multiplicity and structure of UDP-glucuronosyl-transferases as revealed by gene cloning. In: Miners J, Birkett DJ, Drew R, McManus M, eds. Microsomes and drug oxidations. London: Taylor and Francis, 1988:271–8.Google Scholar
  22. 22.
    Watkins JB, Klaassen CD. Effects of inducers and inhibitors of glucuronidation on the biliary excretion and choleretic action of valproic acid in the rat. J Pharmacol Exp Ther 1982;220(2):305–10.PubMedGoogle Scholar
  23. 23.
    Perucca E, Gatti G, Frigo GM, Crema A, Calzetti S, Visintini D. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978;5:495–9.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • Gérard Fabre
    • 1
  • Christophe Briot
    • 1
  • Eric Marti
    • 1
  • Jean -Pierre Montseny
    • 1
  • Martine Bourrié
    • 1
  • Danielle Massé
    • 1
  • Yves Berger
    • 1
  • Jean -Paul Cano
    • 2
  1. 1.Sanofi RechercheMontpellier, Cédex 04France
  2. 2.Ministère Chargé de la SantéParis 07 SPFrance

Personalised recommendations